Scilex (SCLX) Expected to Announce Quarterly Earnings on Monday

Scilex (NASDAQ:SCLX) is expected to release its earnings data before the market opens on Monday, May 12th. Analysts expect Scilex to post earnings of ($0.09) per share and revenue of $17.79 million for the quarter.

Scilex Stock Performance

Scilex stock opened at $4.01 on Friday. The company has a market capitalization of $27.88 million, a PE ratio of -4.83 and a beta of 1.10. The company has a 50 day moving average price of $7.82 and a 200-day moving average price of $15.04. Scilex has a fifty-two week low of $3.60 and a fifty-two week high of $80.50.

Analysts Set New Price Targets

SCLX has been the subject of several research reports. D. Boral Capital reiterated a “hold” rating on shares of Scilex in a report on Friday, April 11th. D Boral Capital lowered shares of Scilex from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $455.00.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.